🔎 Trials Near Me

Inicio › Cáncer de pulmón › Carolina del Norte

Ensayos clínicos de Cáncer de pulmón en Carolina del Norte

50 estudios sobre Cáncer de pulmón buscan participantes en Carolina del Norte.

Ciudades en Carolina del Norte

Texto oficial del estudio (inglés)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Durham VA Medical Center, Durham
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06995898

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • Southeastern Medical Oncology Center-Jacksonville, Jacksonville
ReclutandoFase 3
Edades de 70 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06096844

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Wake Forest University at Clemmons, Clemmons
  • y 8 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04267848

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Novant Health Presbyterian Medical Center, Charlotte
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • y 7 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04181060

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Duke University, Durham
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • Novant Health Cancer Institute - Kernersville, Kernersville
  • Novant Health Cancer Institute - Mount Airy, Mount Airy
  • Novant Health Forsyth Medical Center, Winston-Salem
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07059884

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AdventHealth Infusion Center Asheville, Asheville
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • AdventHealth Infusion Center Haywood, Clyde
  • y 6 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT05334069

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Duke Cancer Center Cary, Cary
  • Durham VA Medical Center, Durham
  • Duke University Medical Center, Durham
  • y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • Carolinas Medical Center, Charlotte
  • Duke Cancer Center, Durham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109

A Study of PHN-012 in Patients With Advanced Solid Tumors

  • PHN-012-001 Site, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07127874

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06881784

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  • GSK Investigational Site, Wilson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07099898

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Messino Cancer Centers Asheville, Asheville
  • Duke University Medical Center, Durham
  • FirstHealth Cancer Center, Pinehurst
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 25 sept 2026 · NCT05920356

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
  • FirstHealth Moore Regional Hospital, Pinehurst
  • Carolina Cancer Research Center, Wilson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Brody School of Medicine at East Carolina University, Greenville
  • ECU Health Medical Center, Greenville
  • Carolina Cancer Research Center, Wilson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06758401

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

  • GSK Investigational Site, Wilson
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07602855

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06712316

Study of Trilaciclib and Lurbinectidin

  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05578326

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
  • Wake Forest University Health Sciences, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06287775

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07685938

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Duke University School of Medicine, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05786924

Effects of Infusion Timing on Treatment Response in Solid Tumors

  • University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07630168

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of North Carolina Medical Center, Chapel Hill
  • Duke Cancer Institute, Durham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581

Health Education Approach to Lung Screening

  • University of North Carolina-Chapel Hill, Carrboro
ReclutandoSe aceptan voluntarios sanos
Edades de 50 a 80 · Todos los sexos · Actualizado el 25 ago 2026 · NCT06070870

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Atrium Health Stanly/LCI-Albemarle, Albemarle
  • Duke Cancer Center Cary, Cary
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • y 35 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05624996

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Charlotte
  • Xencor Investigative Site, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 ago 2026 · NCT05433142

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Duke University Medical Center, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT05652686

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT06896162

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

  • Levine Cancer Institute, Charlotte
ReclutandoSe aceptan voluntarios sanos
Edades de 40 a 54 · Todos los sexos · Actualizado el 13 jul 2026 · NCT04577599

Integrated Cancer Repository for Cancer Research

  • Cape Fear Valley Health System, Fayetteville
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of North Carolina, Chapel Hill
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 26 jun 2026 · NCT04614103

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

  • Research Site, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT06835569

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Durham VA Medical Center, Durham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT05642572

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  • Duke Cancer Center, Durham
  • Carolina BioOncology Institute, Huntersville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT06040541

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • University of North Carolina at Chapel Hill, Chapel Hill
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 may 2026 · NCT06922591

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Durham VA Medical Center, Durham
  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
ReclutandoFase 2
18 Minutes · Todos los sexos · Actualizado el 5 may 2026 · NCT06031688

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 abr 2026 · NCT05168566

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.